Therefore, the gene set identified in our analysis appears to perform better in predicting the response to ICI therapies targeting CD8+ T cells and inflammatory cytokine gene signature within the tumor tissue than those targeting CD4+ T cells and T regulatory cells. This evidence concerns the gene CD8A and neoplasm.